logo-loader

Silence Therapeutics 'in a hot space with few competitors'

Published: 21:10 12 Jun 2018 AEST

Silence Therapeutics' (LON:SLN) executive chair Annalisa Jenkins sat down with Proactive's Andrew Scott to discuss her strategy for taking the drug developer forward and the 'exciting opportunities' in the RNAi space.

On what attracted Jenkins to join Silence, she says: ''The opportunity to be at a good company with a great platform, based in Europe and in a space that I think is at a really disruptive moment in time in terms of doing great things for patients''.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

3 hours, 36 minutes ago